Faculty, Staff and Student Publications
Publication Date
1-23-2024
Journal
Blood Advances
Abstract
High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (≥CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; P < .0001) in the early-relapse (
Keywords
Humans, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Lenalidomide, Multiple Myeloma, Neoplasm Recurrence, Local
DOI
10.1182/bloodadvances.2023010579
PMID
38048391
PMCID
PMC10820288
PubMedCentral® Posted Date
December 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Comments
This article has been corrected. See Blood Adv. 2024 May 14; 8(9): 2148.